Submission Details
| 510(k) Number | K213882 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | December 13, 2021 |
| Decision Date | June 08, 2022 |
| Days to Decision | 177 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
K213882 is an FDA 510(k) clearance for the EarliPoint System, a Pediatric Autism Spectrum Disorder Diagnosis Aid (Class II — Special Controls, product code QPF), submitted by Earlitec Diagnostics, Inc. (Atlanta, US). The FDA issued a Cleared decision on June 8, 2022, 177 days after receiving the submission on December 13, 2021. This device falls under the Neurology review panel. Regulated under 21 CFR 882.1491.
| 510(k) Number | K213882 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | December 13, 2021 |
| Decision Date | June 08, 2022 |
| Days to Decision | 177 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
| Product Code | QPF — Pediatric Autism Spectrum Disorder Diagnosis Aid |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 882.1491 |
| Definition | A Pediatric Autism Spectrum Disorder Diagnosis Aid Is A Prescription Device That Is Intended For Use As An Aid In The Diagnosis Of Autism Spectrum Disorder In Pediatric Patients. |